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Conclusion: CHF LOS and cost in patients cared for by FP/lM can be
reduced by an intensive EP based on ACC/AHA guidelines.
m977158 Clinicai Determinants of Outcome in AdvancedHeart Faiiure: insighte from the PRAISE Triai
C.M. O’Connor, S.A. Anderson, R.B. Meese, J.K. Ghali, W.D. Old,
P.W.Willis, J.A. Bowers, D.A. Bramlet, A.B. Cropp, D.L. DeMets. Duke
University Medical Centec Durham, NC, USA
Understanding the relationship between baseline prognostic characteristics
and heart failure patients’ risk of death can help clinicians determine the
appropriate use of therapeutic strategies and facilitate the design of future
clinical trials.
In the PRAISE Trial of advanced heatt failure, 1,153 patients were ran-
domized to receive Amlcdipine vs placebo in addition to digitalis, diuretics
and ACE inhibitore. Baseline characteristics with respect to survival status
are shown below:
BsselineCharacteristics Alive Dead
Ags(yre.)(medianIQrangs) 65(57-72) 67(60-73)
IsohemicEtiology 59% 71”/0
NYHAClassIV 15% 26”/a
BloodPressure(SBP)mmHg 120(106-130) 110(100-124)
LVEF 21(17-25) 20 (15-25)
The independent predictor of outcome were: SBP (X2= 41), pulse pres-
sure (X2= 20), oerdiothoracic ratio (X2= 19), sodium level (X2= 18), low
weight (kg) (X2= 16), NYHA Class (X2= 15), LVEF (X2= 14), etiology (X2=
13), race (X2= 12), Ml hx (X2= 12), anti-arrhythmia drug hx (X2= 9), nitrate
use hx (X2= 7), aga (X2= 6), disease durstion (X2= 5), and hypertension hx
(X2,= 5).
In mnclusion, simple baseline clinical characteristics can discriminate
high risk from low risk heart failure patients and thus, may help clinicians
decide on the use of more aggressive therapiea and the design of future
clinical trials.
m977159 Contemporary Pattarns of Practice and Outcomesin Congestive Heart Faiiure Patiants Treated in a
Specialized Ciinic
K.K. Tee, F.A.McAliater, M. Taher, D.P.Humeri, R. Yim, L. Cheung, M. Kiaii,
T.J. Montague, P.W.Armstrong. University of A/Lrerta,.Edmorrton,Alberta,
Canada
Thia study reporle on the contemporav patterns of practice and outcomea in
586 consecutive patients referred to and followed up for an average of 51S
+ 490 days in a specialized CHF clinic attended by specialized medical and
nursing staff in a tertiary care hospital. Average age at initial presentation
was 68 + 14 years, 382 (6S%) were male, 380 (677.) had ikohemic heart
diseaae, 441 (76%) had systolic and the reet (22%) diastolic dysfunction. At
entry, 12% were in NYHA class 1,35% class H,36Y0class III and 15% class
IV. Medication used at last follow-up included ACE inhibitor (60%), loop
diuretics (80%), digoxin (60%), nitrates (49%), aapirin (60%), warfarfn (37%),
betablockers (26%), calcium channel blockers (18%), amiodarone (7%) and
magnesium supplement (9%).The most commonly prescribed ACE inhibitors
were enalapril (61Y0,mean dose 10.7 mg/day), Iisinopril (28%, 10.3 mg/day)
and captopril (9%, 62.1 m~day). Lifetable analysis showed one year survival
rates to be 90% for NYHA claas 1,86Y0for class H,777. class Ill and 56?4
class IV.Two year survival rates were 84%, 79Y0,66Y0and 34%, respectively.
Multivariate logistic regression analysis revealed that increased mortality riak
was associated with age >70 years (odds ratio [OR], 1.7, p = 0.01), NYHA
class IV (OR2.4, P= O.01),serum creatinine >130mmol/L (OR2.5, p= O.001)
and aystolic dysfunction (OR 2.1, p = 0.001). Betablockers were associated
with decreaaed mortality risk (OR 0.4, p = 0.002) while metolazone (OR 2.3,
P = 0.005) thiazides (OR 2.1, p = 0.05) and nitrates (OR 1.6, p = 0.03) were
associated with increased mortality risk. Compared to historical data, e.g.
the SOLVD Registv, these data suggest that treatment of patients with CHF
can be enhanced in a special CHF clinic with associated improved outcome.
1977-1601 patient SeieCtiOnforVentricuiar Ramodeiing
Surgery: Evoiving Criteria and Outcomes
R.C. Starling, J.B. Young, T.M. Buda, R.L. Vargo, N.G. Smedira,
P.M.McCarthy. The C/eve/and C/inic Foundation, C/eve/and, Ohio, USA
The Ieftventricular remodeling procedure (LVR) has been recently developed
as a treatment for patients (pts) with congestive heart failure (CHF). Some
centers have proposed that meet etiologies of heart disease will respond and
have reported perioperative mortality of ?25%. We believed that patients
with extensive coronary disease and prior infarction, irreversible myooyte
damage (e.g., adriamycin toxicity), primary myooyte diaorders and LV end
diastolic diameter (LVIDd) <7.0 cm would not be appropriate for LVR. Using
these criteria, 17 patients, 11 male, mean age 50.2 years, have undergone
LVR. Five patients were on chronic dobutamine pre-op, and 4 required
inotropic support during anesthesia induction. Operative mortality is O%,
and there have bean no deaths since the initial case was performed 105
days ago. The mean weight of LV mass resected was 78 + 31 grams (36-
136). Fourteen patients have been discharged. Two patients have required
post LVR support with an LV assist device; one had normal coronaries but
unrecognized remote infarction of the anteroseptal wall, and one sustained
an infarct perioperatively. One patient was found to have active myocerditia
after muscle resection and has required inotropic suppoti. The remaining
patients’ cardiac pathology has shown myocyte hypertrophy and interetiai
fibrosis (IF). Outcome cannot be predicted on the baais of extent of IF. We
believe that careful evaluation and selection criteria will define a patient
population likely to benefit from the LVR.
~977-1731prOgnOSiSandprOgreSSiOnOfEariyFaMiiiai
Diiated Cardiomyopathy: A 30 Month Prospective
Study
M.K. Baig, J.H. Goldman, AS. Coonar, A.L.P. Caforio, S. Sharma,
W.J. McKenna. St Georges Hospital, London, UK
Background: A subset of patients with dilated cardiomyo@hy (DCM) have
familial diseaae. We prospectively assessed relatives with abnormalities
suggestive of early diseaae.
Mathod:406asymptomatic relatives (mean age35 + 15,193 male) of 110
DCM patienta were assessed with non invasive cardiological assessment.
Results: 45 (20Yo)had LV enlargement (LVE ? 112% predicted), 13 (6%)
had depressed fractional shortening (FS -= 25%), 7 (3Yo)had established
DCM, and the remainder were normal. Abnormal WA ratio waa found in 40
(6S%) LVE and 60 (41%) normals. Relatives with LVE had lower E/A ratio,
lower % fs and larger LA dimensions than normale (1.29 + 0.72 vs 1.80
+ 0.71, p = 0.04), (33 + 6 VS35 + 6, p = 0.003), (35 + 5 VS33 + 5, p
= 0.001), reapactively. V02 max was abnormal in more LVES compared to
normals (4.9% vs 2.17., p < 0.05). LVE with abnormal VOZ % (<80Y0) had
a lower absolute VOZ max compared to normals (30 + 7.8 vs 42.5 + 9.1,
P = 0.01). dFS’s had larger LVDD% predicted (112 + 13 vs 102 + 7, p <
0.001), and lower RMS voltage.(30 * 8.9 mv vs 57.6 + 39.6 mv, p = 0.05)
than normals. Over 33 + 80.8 months follow-up, 12 LVE (27%), O relatives
with dFS, and 3 normal relatives (2%) developed DCM (p < 0.0001). Two
relatives with LVE died. No parameter at initial presentation waa predictive
of dieease progression.
Conclusions: 29% of asymptomatic relatives have echocerdiographic ab-
normalities, of whom 27% have progressed to develop overt DCM. The other
abnormalities aleo obsetved support the fact that these relatives have early
disease.
1977-1741 Does GendarHaveanimpacton Survival of
Patients With Heart Faiiure? Findings From the
SOLVD Regiatry
J.K. Ghali, D.H. Weiner, B. Greenberg, K. Adams, C. Benedict,
M. Quinones, for the SOLVD Registry Investigators. Louisiana State
University Shreveport, Louisiana, USA
The effect of gender on aurvival in patients with Heart failure (HF) and the
interaction with LV systolic function have not been well delineated. In order
to determine the effect of gender on long-term prognosis of patients with
Characteristics Males(n= 606) Females(n= 179)
NYHAI 217(36”/.) 55(31%) NS
II 290(460/.) 92(510/.)
Ill 69(15”/0) 29 (160/.)
PulmonaV congestion 139 (27”/.) 45 (29”/.) NS
LVEF > 450/a 156 (259A) 66 (360A) p <0.001
LVEF s 45”/0 461 (75”/0) 113 (62”A)
Heart Rate (bpm) 74.6 l 14.2 7S.1 + 14.2 p <0,005
CardioThoracicRatio 0,52 + 0.07 0.56 + 0.0S p <0.001
